Equashield Surpasses 500 US Customers, Sees Sales Increase of 70% in Q3 of 2016

NOVEMBER 07, 2016
PRESS RELEASE

PORT WASHINGTON – (November 7, 2016) – Equashield, a leading provider of closed system transfer devices (CSTDs) for safe and simple handling of hazardous drugs, today announced that, as of the end of the third quarter of 2016, it has surpassed 500 customers in the United States, indicative of the market’s preference for the company’s Equashield® device. 
 
“Equashield continues to build momentum, and we anticipate additional significant growth in the coming year, as the market increases its understanding of the safety resulting from closed systems,” said Marino Kriheli, co-founder of Equashield. “In addition to complying with NIOSH, ONS and USP 800 recommendations, studies have shown Equashield to be one of the safest and most efficient closed systems on the market.”
 
The results of a 2016 independent series of CSTD Tests utilizing, among others, the proposed NIOSH Vapor Protocol, revealed Equashield to be the only device not to show any sign of leakage. In addition, results of previous studies show Equashield® to be quicker and easier to use than other leading devices.
 
About Equashield 
Equashield is a leading provider of Closed System Transfer Devices (CSTDs), clinically proven to protect healthcare professionals from hazardous drug exposure. Incorporating a pioneering design, the company’s flagship device, EQUASHIELD® II, covers more routes of exposure than alternative systems by preventing contamination of syringe plungers and drug residuals on connector surfaces, as well as exposure to drug vapor. Studies have shown Equashield’s CSTD to be faster to deploy and easier to use than competing systems, and the system has passed NIOSH’s proposed vapor containment protocol, confirming that it can contain vapors/emissions within the limits of the proposed testing. The EQUASHIELD system has been cleared by the FDA under the ONB product code and substantiated in FDA-cleared labeling as preventing microbial ingress for up to seven days. 
 
 
 

SHARE THIS SHARE THIS
1
Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.